Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

Randy M Stalter; Jared M Baeten; Deborah Donnell; Matthew A Spinelli; David V Glidden; Warren C Rodrigues; Guohong Wang; Michael Vincent; Nelly Mugo; Andrew Mujugira; Mark Marzinke; Craig Hendrix; Monica Gandhi; Partners PrEP Study Team

doi:10.1093/cid/ciaa785

Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

Clin Infect Dis. 2021 Feb 1;72(3):486-489. doi: 10.1093/cid/ciaa785.

Authors

Randy M Stalter^{1

2}, Jared M Baeten^{1

2

3}, Deborah Donnell^{1

4}, Matthew A Spinelli⁵, David V Glidden⁵, Warren C Rodrigues⁶, Guohong Wang⁶, Michael Vincent⁶, Nelly Mugo^{1

7}, Andrew Mujugira^{1

8}, Mark Marzinke⁹, Craig Hendrix⁹, Monica Gandhi⁵; Partners PrEP Study Team

Collaborators

Affiliations

¹ Department of Global Health, University of Washington, Seattle, Washington, USA.
² Department of Epidemiology, University of Washington, Seattle, Washington, USA.
³ Department of Medicine, University of Washington, Seattle, Washington, USA.
⁴ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁵ Division of HIV, ID, and Global Medicine, University of California-San Francisco, San Francisco, California, USA.
⁶ Toxicology Division, Abbott Rapid Diagnostics, Pomona, California, USA.
⁷ Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
⁸ Infectious Diseases Institute, Makerere University, Kampala, Uganda.
⁹ Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Abstract

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.

Keywords: PrEP; ELISA; HIV prevention; immunoassay; urine.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents* / therapeutic use
Emtricitabine / therapeutic use
HIV
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Immunoassay
Medication Adherence
Pre-Exposure Prophylaxis*
Tenofovir / therapeutic use

Substances

Anti-HIV Agents
Tenofovir
Emtricitabine

Abstract

Publication types

MeSH terms

Substances

Grants and funding